JPH09511747A - スギ花粉アレルギーを治療するための医薬組成物 - Google Patents
スギ花粉アレルギーを治療するための医薬組成物Info
- Publication number
- JPH09511747A JPH09511747A JP7526440A JP52644095A JPH09511747A JP H09511747 A JPH09511747 A JP H09511747A JP 7526440 A JP7526440 A JP 7526440A JP 52644095 A JP52644095 A JP 52644095A JP H09511747 A JPH09511747 A JP H09511747A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cji
- peptide
- peptides
- cedar pollen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000218645 Cedrus Species 0.000 title claims abstract description 48
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 title abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 6
- 206010048908 Seasonal allergy Diseases 0.000 title abstract description 3
- 201000004338 pollen allergy Diseases 0.000 title abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 254
- 239000000203 mixture Substances 0.000 claims abstract description 98
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 32
- 239000013573 pollen allergen Substances 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 9
- 230000007815 allergy Effects 0.000 claims abstract description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 110
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 71
- 239000013566 allergen Substances 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- 229930195725 Mannitol Natural products 0.000 claims description 10
- 239000000594 mannitol Substances 0.000 claims description 10
- 235000010355 mannitol Nutrition 0.000 claims description 10
- 208000026935 allergic disease Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 7
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 6
- 239000001488 sodium phosphate Substances 0.000 claims description 6
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 6
- 230000035945 sensitivity Effects 0.000 claims description 2
- 239000008227 sterile water for injection Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000001647 drug administration Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 22
- 108091005601 modified peptides Proteins 0.000 abstract description 3
- 230000009257 reactivity Effects 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 230000000638 stimulation Effects 0.000 description 19
- 150000001413 amino acids Chemical group 0.000 description 18
- 208000010668 atopic eczema Diseases 0.000 description 17
- 230000000172 allergic effect Effects 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 230000005867 T cell response Effects 0.000 description 15
- 240000005109 Cryptomeria japonica Species 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
- 206010002198 Anaphylactic reaction Diseases 0.000 description 7
- 208000003455 anaphylaxis Diseases 0.000 description 7
- 238000004364 calculation method Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 230000006052 T cell proliferation Effects 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000036783 anaphylactic response Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000004043 responsiveness Effects 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000012062 aqueous buffer Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000011008 sodium phosphates Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000226709 Hesperocyparis arizonica Species 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000721662 Juniperus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- -1 Troches Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000723436 Chamaecyparis obtusa Species 0.000 description 2
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- 101800004637 Communis Proteins 0.000 description 2
- 101001123585 Cryptomeria japonica Pectate lyase 1 Proteins 0.000 description 2
- 241000723198 Cupressus Species 0.000 description 2
- 241001290232 Hesperocyparis macrocarpa Species 0.000 description 2
- 241000721668 Juniperus ashei Species 0.000 description 2
- 241000592238 Juniperus communis Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000218636 Thuja Species 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101800000884 C-terminal-flanking peptide Proteins 0.000 description 1
- 102400000095 C-terminal-flanking peptide Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000573484 Copsychus Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001531917 Juniperus virginiana Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710126321 Pancreatic trypsin inhibitor Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 235000008691 Sabina virginiana Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000004182 chemical digestion Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- UNXNGGMLCSMSLH-UHFFFAOYSA-N dihydrogen phosphate;triethylazanium Chemical compound OP(O)(O)=O.CCN(CC)CC UNXNGGMLCSMSLH-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- PZJSVHARXVPCTD-UHFFFAOYSA-N fluoro(propoxy)phosphinic acid Chemical compound CCCOP(O)(F)=O PZJSVHARXVPCTD-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000012177 negative regulation of immune response Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 108010091748 peptide A Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.CJI-43.39(配列番号36)、CJI-24.5(配列番号37)、CJI-44.8(配列番号3 8)から成る群か選択されるアミノ酸配列を有する、単離されたCryiIペプチド。 2.CJI-43.39(配列番号36)、CJI-24.5(配列番号37)、CJI-44.8(配列番号3 8)から成る群か選択される少なくとも1つの単離されたCryjIペプチドを含んで 成る治療用組成物。 3.請求の範囲第2項に記載の少なくとも2つの異なる組成物を連続的または同 時に投与することを含んで成る、スギ花粉アレルゲンまたはスギ花粉アレルゲン と免疫的に交叉反応性のアレルゲンに対する感受性を処置する方法。 4.医薬的に許容できる状態のペプチドCJI-43.39(配列番号36)、CJI-24.5(配 列番号37)、CJI-44.8(配列番号38)を連続的または同時に投与することを含 んで成る、スギ花粉アレルゲンまたはスギ花粉アレルゲンと免疫的に交叉反応性 のアレルゲンに対する感受性を処置する方法。 5.各ペプチドがT細胞活性を有し、各ペプチドが可溶性であり、そして生理的 に許容できる予め定めたpHで安定である、CJI-43.39(配列番号36)、CJI-24. 5(配列番号37)、CJI-44.8(配列番号38)から成る群か選択される少なくとも 2つのCryjIペプチド、および医薬的に許容できる賦形剤を含んで成る薬剤投与 のためのマルチペプチド組成物。 6.さらに医薬的に許容できる対イオンを含んで成る、請求の範囲第5項に記載 のマルチペプチド組成物。 7.上記の予め定めたpHが、約pH5.5から7.5の範囲である、請求の範 囲第5項に記載のマルチペプチド組成物。 8.ペプチドCJI-42.5(配列番号42)、CJI-43.39(配列番号36)、CJI-24.5(配 列番号37)、CJI-44.8(配列番号38)を含んで成る、請求の範囲第5項に記載 のマルチペプチド組成物。 9.上記T細胞活性が少なくとも39%である、請求の範囲第2項に記載のマルチ ペプチド組成物。 10.CryjIペプチドCJI-24.5(配列番号37)、CJI-43.39(配列番号36)および CJI-44.8(配列番号38)、各ペプチドはペプチドあたり0.75mgの濃度を有する; 0.05M リン酸ナトリウム、pH6.0-8.0; 5% 重量/容量マンニトール、U.S.P.;および 注射用滅菌水、U.S.P. を含んで成る、スギ花粉に対するアレルギーに罹患しているヒトの治療的処置に 適する至適化されたマルチペプチド組成物。 11.上記組成物が凍結乾燥状態である、請求の範囲第10項に記載の至適化さ れたマルチペプチド組成物。 12.組成物の最終pHがpH7.0からpH7.5のpH範囲である、請求の範囲第10 項に記載の至適化されたマルチペプチド組成物。 13.スギ花粉アレルゲンまたはスギ花粉アレルゲンと免疫的に交叉反応性のア レルゲンに対する個体の感受性を処置するための医薬品を製造するための、請求 の範囲第2項に記載の治療用組成物の使用。 14.スギ花粉アレルゲンまたはスギ花粉アレルゲンと免疫的に交叉反応性のア レルゲンに対する個体の感受性を処置するための医薬品を製造するための、請求 の範囲第5項に記載のマルチペプチド組成物の使用。 15.スギ花粉アレルゲンまたはスギ花粉アレルゲンと免疫的に交叉反応性のア レルゲンに対する個体の感受性を処置するための医薬品を製造するための、請求 の範囲第10項に記載の至適化されたマルチペプチド組成物の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22624894A | 1994-04-08 | 1994-04-08 | |
US08/226,248 | 1994-04-08 | ||
US35022594A | 1994-12-06 | 1994-12-06 | |
US08/350,225 | 1994-12-06 | ||
PCT/US1995/004249 WO1995027786A1 (en) | 1994-04-08 | 1995-04-06 | Pharmaceutical formulations for treating japanese cedar pollen allergy |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09511747A true JPH09511747A (ja) | 1997-11-25 |
JP4179422B2 JP4179422B2 (ja) | 2008-11-12 |
Family
ID=26920341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52644095A Expired - Lifetime JP4179422B2 (ja) | 1994-04-08 | 1995-04-06 | スギ花粉アレルギーを治療するための医薬組成物 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0756629A1 (ja) |
JP (1) | JP4179422B2 (ja) |
AU (1) | AU2241995A (ja) |
CA (1) | CA2187336A1 (ja) |
WO (1) | WO1995027786A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007505911A (ja) * | 2003-09-17 | 2007-03-15 | ベイビー・ブースト,インコーポレイテッド | アレルギーを予防する方法および装置 |
JP2012240975A (ja) * | 2011-05-20 | 2012-12-10 | Nitto Denko Corp | 医薬組成物及びゼリー状製剤 |
JP2012240978A (ja) * | 2011-05-20 | 2012-12-10 | Nitto Denko Corp | 医薬組成物及びゼリー状製剤 |
JP2013163662A (ja) * | 2012-02-10 | 2013-08-22 | Ostrich Pharma Kk | 抗体含有花粉アレルギー防御素材 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69630877T2 (de) * | 1995-03-31 | 2004-11-11 | Xenova Research Ltd., Slough | Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie |
US5773003A (en) * | 1995-03-31 | 1998-06-30 | Immulogic, Inc. | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
JP4176750B2 (ja) * | 1996-06-14 | 2008-11-05 | 明治乳業株式会社 | T細胞エピトープペプチド |
CN102286077A (zh) * | 1996-06-14 | 2011-12-21 | 明治乳业株式会社 | T细胞表位肽 |
SE9603468D0 (sv) * | 1996-09-23 | 1996-09-23 | Astra Ab | New compounds |
SE9603463D0 (sv) * | 1996-09-23 | 1996-09-23 | Astra Ab | New compounds |
US7025964B1 (en) * | 1996-11-13 | 2006-04-11 | Meiji Dairies Corporation | Peptide-based immunotherapeutic agent |
JP3939401B2 (ja) * | 1997-09-17 | 2007-07-04 | 三共株式会社 | ペプチド及びその用途 |
US6232082B1 (en) | 1998-12-01 | 2001-05-15 | Nabi | Hapten-carrier conjugates for treating and preventing nicotine addiction |
JP3987563B2 (ja) * | 2006-10-23 | 2007-10-10 | 第一三共株式会社 | ペプチド及びその用途 |
JP3987562B2 (ja) * | 2006-10-23 | 2007-10-10 | 第一三共株式会社 | ペプチド及びその用途 |
EP2524701A3 (en) * | 2011-05-20 | 2012-12-19 | Nitto Denko Corporation | Pharmaceutical composition and method for producing the same |
WO2016209959A2 (en) | 2015-06-22 | 2016-12-29 | Alk-Abelló A/S | Peptide combinations and use thereof in treating cedar pollen allergy |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994001560A1 (en) * | 1991-07-12 | 1994-01-20 | Immulogic Pharmaceutical Corporation | Allergenic proteins and peptides from japanese cedar pollen |
-
1995
- 1995-04-06 CA CA002187336A patent/CA2187336A1/en not_active Abandoned
- 1995-04-06 EP EP95915576A patent/EP0756629A1/en not_active Withdrawn
- 1995-04-06 AU AU22419/95A patent/AU2241995A/en not_active Abandoned
- 1995-04-06 WO PCT/US1995/004249 patent/WO1995027786A1/en not_active Application Discontinuation
- 1995-04-06 JP JP52644095A patent/JP4179422B2/ja not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007505911A (ja) * | 2003-09-17 | 2007-03-15 | ベイビー・ブースト,インコーポレイテッド | アレルギーを予防する方法および装置 |
JP2012240975A (ja) * | 2011-05-20 | 2012-12-10 | Nitto Denko Corp | 医薬組成物及びゼリー状製剤 |
JP2012240978A (ja) * | 2011-05-20 | 2012-12-10 | Nitto Denko Corp | 医薬組成物及びゼリー状製剤 |
JP2013163662A (ja) * | 2012-02-10 | 2013-08-22 | Ostrich Pharma Kk | 抗体含有花粉アレルギー防御素材 |
Also Published As
Publication number | Publication date |
---|---|
WO1995027786A1 (en) | 1995-10-19 |
EP0756629A1 (en) | 1997-02-05 |
AU2241995A (en) | 1995-10-30 |
CA2187336A1 (en) | 1995-10-19 |
JP4179422B2 (ja) | 2008-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09511747A (ja) | スギ花粉アレルギーを治療するための医薬組成物 | |
NZ502480A (en) | Pharmaceutical peptide formulations for treatment of dust mite allergy | |
JP2002223783A (ja) | ピーナッツアレルゲンおよび方法 | |
CN102762225B (zh) | 用于针对桦树过敏的疫苗的肽 | |
EA020792B1 (ru) | Пептиды трав для вакцины | |
JPH09504167A (ja) | ドクムギ花粉アレルゲンのt細胞エピトープ | |
AU717187B2 (en) | Pharmaceutical peptide formulations for treatment of dust mite allergy | |
EP0803511A1 (en) | Allergenic proteins from ragweed and uses therefor | |
JPH07507924A (ja) | アンブロシア・アルテミシフォリア由来の主要アレルゲンのt細胞エピトープ | |
CA2558660C (en) | Fusion proteins comprising modified allergens of the ns-ltps family, use thereof and pharmaceutical compositions comprising the same | |
JP3649460B2 (ja) | スギ花粉アレルゲンCry j IIエピトープ | |
US6335020B1 (en) | Allergenic peptides from ragweed pollen | |
JPH10506877A (ja) | ライグラス花粉アレルゲンのt細胞エピトープ | |
CA2157980A1 (en) | Allergenic peptides from cryptomeria japonica and their uses | |
JP3445593B2 (ja) | ペプチドとその用途 | |
JP3588166B2 (ja) | ペプチドとその用途 | |
JP3734855B2 (ja) | ペプチド及びその用途 | |
JP3588165B2 (ja) | ペプチドとその用途 | |
KR100562821B1 (ko) | T세포에피토프펩티드 | |
JPH08176192A (ja) | ヒノキ花粉アレルゲン | |
JP2004323530A (ja) | ペプチドとその用途 | |
NZ616746A (en) | Hypoallergen | |
NZ616746B2 (en) | Hypoallergen | |
JP2004357717A (ja) | スギ花粉アレルゲンCryjIIエピトープ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041124 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050224 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050411 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050524 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050705 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050921 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060104 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060915 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070720 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20070808 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071218 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080314 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080428 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080610 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080812 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080820 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080806 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110905 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120905 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130905 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |